See more : XcelPlus International, Inc. (XLPI) Income Statement Analysis – Financial Results
Complete financial analysis of Lexaria Bioscience Corp. (LEXX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lexaria Bioscience Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Socialwire Co., Ltd. (3929.T) Income Statement Analysis – Financial Results
- JK Holdings Co., Ltd. (9896.T) Income Statement Analysis – Financial Results
- Codexis, Inc. (0I0X.L) Income Statement Analysis – Financial Results
- Prithvi Exchange (India) Limited (PRITHVIEXCH.BO) Income Statement Analysis – Financial Results
- Beijing ConST Instruments Technology Inc. (300445.SZ) Income Statement Analysis – Financial Results
Lexaria Bioscience Corp. (LEXX)
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 464.28K | 226.21K | 255.40K | 722.74K | 384.54K | 222.61K | 433.29K | 63.64K | 40.72K | 14.70K | 1.10M | 1.36M | 1.13M | 362.47K | 421.96K | 900.79K | 253.15K | 20.31K | 20.31K |
| Cost of Revenue | 4.82K | 31.50K | 71.84K | 175.35K | 99.38K | 22.89K | 25.19K | 29.75K | 45.62K | 29.88K | 795.20K | 783.27K | 667.86K | 273.62K | 548.32K | 912.75K | 124.91K | 93.32K | 93.32K |
| Gross Profit | 459.46K | 194.71K | 183.56K | 547.39K | 285.17K | 199.72K | 408.10K | 33.89K | -4.90K | -15.18K | 302.25K | 574.49K | 465.91K | 88.86K | -126.37K | -11.96K | 128.24K | -73.01K | -73.01K |
| Gross Profit Ratio | 98.96% | 86.07% | 71.87% | 75.74% | 74.16% | 89.72% | 94.19% | 53.25% | -12.03% | -103.26% | 27.54% | 42.31% | 41.09% | 24.51% | -29.95% | -1.33% | 50.66% | -359.55% | -359.55% |
| Research & Development | 2.36M | 3.67M | 1.84M | 1.26M | 387.07K | 555.73K | 492.86K | 54.19K | 9.02K | 146.47K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 3.85M | 3.06M | 5.72M | 4.97M | 3.57M | 3.13M | 6.02M | 1.63M | 1.01M | 1.49M | 1.27M | 561.89K | 678.09K | 466.67K | 458.04K | 475.34K | 1.01M | 121.44K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 204.28K | 515.36K | 489.06K | 209.03K | 185.46K | 276.56K | 8.19K | 3.47K | 40.92K | 559.00 | 930.00 | 4.11K | 20.07K | 20.07K | 0.00 |
| SG&A | 3.85M | 3.06M | 5.72M | 4.97M | 3.77M | 3.64M | 6.51M | 1.84M | 1.20M | 1.76M | 8.19K | 565.35K | 719.01K | 467.23K | 458.97K | 479.45K | 1.03M | 141.51K | 35.14K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 112.75K | 60.55K | 2.31K | -886.00 | 4.60K | -22.66K | 0.00 | 14.04K | 6.40K | 0.00 | 8.21K | 1.28K | 148.38K | -2.99K | 0.00 |
| Operating Expenses | 6.21M | 6.73M | 7.57M | 6.23M | 4.27M | 4.26M | 7.01M | 1.90M | 1.21M | 1.91M | 8.19K | 579.40K | 725.41K | 474.00K | 467.18K | 480.72K | 1.18M | 138.53K | 35.14K |
| Cost & Expenses | 6.22M | 6.76M | 7.64M | 6.41M | 4.37M | 4.28M | 7.03M | 1.92M | 1.26M | 1.94M | 803.40K | 1.36M | 1.39M | 747.61K | 1.02M | 1.39M | 1.30M | 231.85K | 35.14K |
| Interest Income | 14.31K | 43.19K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 94.00 | 4.09K | 18.09K | 6.12K | 6.12K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.02K | 2.25K | 31.54K | 267.36K | 246.61K | 278.73K | 167.32K | 160.12K | 857.58K | 4.71K | 21.91K | 21.91K |
| Depreciation & Amortization | 76.15K | 145.40K | 146.91K | 147.60K | 146.09K | 60.55K | 2.31K | 1.49K | 619.00 | -22.66K | 1.52M | 456.60K | 370.62K | 122.16K | 342.13K | 453.12K | 148.38K | 81.76K | 40.44K |
| EBITDA | -5.68M | -6.39M | -6.52M | -5.58M | -4.00M | -4.10M | -6.61M | -1.92M | -1.26M | -1.95M | 294.06K | -35.30K | 442.73K | 111.12K | -236.15K | -244.37K | -414.37K | -891.03K | -129.78K |
| EBITDA Ratio | -1,222.75% | -2,824.23% | -2,835.72% | -977.11% | -982.78% | -1,752.23% | -1,522.76% | -2,922.37% | -2,983.84% | -13,269.46% | 26.79% | 33.27% | 9.80% | -72.55% | -59.58% | 37.67% | -356.22% | 730.49% | 26.11% |
| Operating Income | -5.75M | -6.53M | -7.38M | -5.69M | -3.89M | -3.96M | -6.60M | -1.86M | -1.22M | -1.93M | 294.06K | -4.90K | -259.50K | -552.46K | -753.67K | -898.09K | -1.05M | -489.66K | -35.14K |
| Operating Income Ratio | -1,239.16% | -2,888.50% | -2,891.05% | -786.85% | -1,012.10% | -1,779.43% | -1,523.29% | -2,924.71% | -2,985.36% | -13,115.30% | 26.79% | -0.36% | -22.89% | -152.42% | -178.61% | -99.70% | -414.83% | -2,411.28% | -173.02% |
| Total Other Income/Expenses | -55.52K | -178.50K | -764.61K | 1.52M | 0.00 | -228.06K | -8.97K | -6.02K | -34.70K | -55.06K | -355.23K | -246.61K | -276.22K | -278.73K | 0.00 | 7.05K | -73.27K | -565.19K | -473.12K |
| Income Before Tax | -5.81M | -6.71M | -7.38M | -4.16M | -4.08M | -4.16M | -6.61M | -1.93M | -1.28M | -1.98M | -1.87M | -251.51K | -538.23K | -552.46K | -753.67K | -971.35K | -1.05M | -211.54K | -75.58K |
| Income Before Tax Ratio | -1,251.12% | -2,967.41% | -2,891.05% | -576.16% | -1,062.20% | -1,868.03% | -1,525.36% | -3,031.89% | -3,136.82% | -13,489.80% | -170.50% | -18.52% | -47.47% | -152.42% | -178.61% | -107.83% | -416.69% | -1,041.70% | -372.16% |
| Income Tax Expense | 0.00 | 0.00 | -114.33K | -1.66M | -54.29K | 39.62K | -8.97K | -54.17K | -60.23K | -181.23K | 294.06K | 246.61K | 278.73K | 167.32K | -94.00 | 7.14K | 1.04K | 574.84K | 40.59K |
| Net Income | -5.80M | -6.66M | -7.27M | -2.50M | -4.03M | -4.20M | -6.60M | -1.87M | -1.21M | -1.77M | -1.87M | -251.51K | -538.23K | -552.46K | -753.57K | -978.49K | -1.06M | -508.26K | -75.72K |
| Net Income Ratio | -1,248.25% | -2,946.36% | -2,846.28% | -346.50% | -1,048.08% | -1,885.83% | -1,522.97% | -2,937.31% | -2,983.38% | -12,042.58% | -170.50% | -18.52% | -47.47% | -152.42% | -178.59% | -108.63% | -417.10% | -2,502.87% | -372.89% |
| EPS | -0.47 | -1.01 | -1.24 | -0.57 | -1.45 | -1.62 | -2.79 | -0.95 | -0.83 | -1.34 | -0.07 | -0.42 | -1.09 | -1.22 | -2.80 | -4.46 | -5.21 | -3.16 | -1.37 |
| EPS Diluted | -0.47 | -1.01 | -1.24 | -0.57 | -1.45 | -1.62 | -2.79 | -0.95 | -0.83 | -1.34 | -0.07 | -0.42 | -1.09 | -1.22 | -2.80 | -4.46 | -5.21 | -3.16 | -1.37 |
| Weighted Avg Shares Out | 12.38M | 6.61M | 5.89M | 4.39M | 2.77M | 2.59M | 2.37M | 1.96M | 1.46M | 1.32M | 25.71M | 602.48K | 493.23K | 451.94K | 268.67K | 219.28K | 202.59K | 160.87K | 55.15K |
| Weighted Avg Shares Out (Dil) | 12.38M | 6.61M | 5.89M | 4.39M | 2.77M | 2.59M | 2.37M | 1.96M | 1.46M | 1.32M | 25.71M | 602.48K | 493.23K | 451.94K | 268.67K | 219.28K | 202.59K | 160.87K | 55.15K |
Cannabis Stocks in Focus This week
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up in 2021.
8 of the Hottest Cannabis Stocks Right Now
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up in 2021.
DehydraTECH(TM) Nicotine Pouches Could Make Smoking Obsolete
New York, New York--(Newsfile Corp. - October 5, 2021) - PCG Digital -- Lexaria Bioscience Corp (NASDAQ: LEXX) is making headlines again this week. In a study conducted by a leading independent testing facility, DehydraTECH™ 2.0 nicotine pouches easily outperformed...
Lexaria Oral Nicotine Study NIC-A21-1 Delivers Outstanding Results
DehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controls Peak levels achieved were up to 10x higher than controls KELOWNA, BC / ACCESSWIRE / October 5, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a...
5 Cannabis Stocks That Lit Up Wall Street This Week
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up in 2021.
BTV News Alert Video: Lexaria Bioscience - The Way to Improve Drugs
Vancouver, British Columbia--(Newsfile Corp. - September 7, 2021) - Lexaria Bioscience (NASDAQ: LEXX) - Lexaria Bioscience began developing DehydraTECH in 2014. Since then, they have strengthened and broadened the technology to an unprecedented degree.If you cannot view the video above,...
CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Results Of Human Clinical Study Showing Effective, Safe BP Reduction
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that its human clinical study HYPER-H21-2, which features LEXX's patented DehydraTECH(TM)-processed cannabidiol (“CBD”), demonstrates up to a 23% decrease in blood pressure when compared to placebo. According to...
Why Lexaria Bioscience Shares Are Trading Higher Today
Lexaria Bioscience Corp (NASDAQ: LEXX) is trading higher Tuesday after the company announced initial results from its human clinical study of DehydraTECH, saying the study evidences up to 23% decrease in blood pressure with DehydraTECH-CBD relative to placebo. Lexaria Bioscience noted that additional...
Lexaria Bioscience's Formulated Cannabidiol Lowers Blood Pressure In Hypertension Patients
Lexaria Bioscience Corp (NASDAQ: LEXX) has announced initial results from human clinical study HYPER-H21-2 evaluating DehydraTECH-processed cannabidiol (CBD) for potential application against hypertension. Related Content: DehydraTECH Delivered Colchicine Can Potentially Treat COVID-19, Side Effects From mRNA Shots.
Lexaria Bioscience Corp. (NASDAQ: LEXX) Targets Burgeoning Hypertension, Antiviral Therapeutics Markets With Drug Delivery Technology
Lexaria has progressed significantly in evidencing that its patented DehydraTECH(TM) drug delivery technology can sufficiently improve the usable fraction of known antiviral drugs that reach the bloodstream. According to a Newsfile Corp. article, this technology can be applied to rendering...
Source: https://incomestatements.info
Category: Stock Reports